Skip to main content
Premium Trial:

Request an Annual Quote

J&J R&D Division Licenses Simcyp's ADME Simulator

NEW YORK (GenomeWeb News) – Johnson & Johnson’s drug research division has licensed Simcyp’s drug modeling and simulation platform, the UK-based firm said today.
 
Through the license, Johnson & Johnson Pharmaceutical Research and Development will provide access to Simcyp’s population-based Simulator and pediatric module to its global R&D teams for a period of three years. The Simcyp platform provides modeling and simulation of drug absorption, distribution, metabolism, and elimination in virtual populations.
 
The Sheffield-based company said its platform allows researchers to identify individuals who are at extreme risk for adverse drug reactions, and allows for the minimization of drug exposure to human and animal volunteers. The platform also can help assess and manage potential interactions between drugs before human studies begin, the company said.
 
Financial terms of the agreement were not released.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.